See every side of every news story
Published loading...Updated

Novo Nordisk's Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease - Novo Nordisk (NYSE:NVO)

  • Novo Nordisk's Ozempic is under scrutiny for a potential increased risk of rare-eye disease.
  • Health authorities are investigating the impact of Ozempic due to concerns from experts.
  • Novo Nordisk is conducting further analysis in response to these concerns.
  • The company emphasizes its commitment to patient safety amid these investigations.
Insights by Ground AI
Does this summary seem wrong?

11 Articles

Lean Left

Two new studies to be published by researchers at the University of Southern Denmark show that the risk of developing this condition, which can go as far as blindness, is doubled in diabetic patients treated with this medication. The side effect is rare, but should be considered if confirmed.

·Paris, France
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 60% of the sources are Center
60% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

CNBC broke the news in United States on Tuesday, December 17, 2024.
Sources are mostly out of (0)

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.